---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010104"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:54:04.558670+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics reports Q2 2024 results; DMT310 Phase 3 trial enrollment over 50%

## Summary
- Net cash $4.9M at June 30, 2024, down from $7.4M at Dec 31, 2023; expects to fund ops into Q4 2024.
- Raised $2.3M in net proceeds from May 2024 warrant inducement financing.
- R&D expenses $2.0M in Q2 2024 vs. $0.8M in Q2 2023 due to STAR-1 trial costs.
- DMT310 Phase 3 STAR-1 trial enrolled over 50% of patients; topline data expected Q1 2025.
- DMT410 partnership discussions ongoing for topical botulinum toxin delivery.

## SEC filing metadata
- accession: 0001654954-24-010104
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424010104/0001654954-24-010104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424010104/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010104
- JSON: https://secwatch.observer/filing/0001654954-24-010104.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.